Company: STAA
Filing Date: 2025-08-29
Form Type: PREM14A
Source: 0001193125-25-192889
Chunk: 71

Company: STAAR SURGICAL CO
Filing Date: 2025-08-29
Form: PREM14A
Chunk 71
---
 following
the signing of a transaction and pay a reduced termination fee of 1% of the implied equity value (approximately $14.5 million) to Alcon if it terminated the merger agreement in response to a superior proposal from a competing bidder that emerged
within the “go-shop” period and would otherwise pay a termination fee of 2.75% of the implied equity value if STAAR terminated the merger agreement to enter into a superior proposal, and
(iv) no fee would be payable by STAAR if its stockholders did not approve the merger.

Also on July 21, 2025, STAAR provided
Alcon and its representatives access to a dataroom to facilitate diligence. During the period from July 21, 2025 until the execution of the Merger Agreement on August 4, 2025, representatives of Alcon and its advisors conducted business
and legal due diligence, and engaged in due diligence discussions with STAAR’s management, representatives and advisors. The diligence focused on, among other things, commercial risks and opportunities, potential synergies, legal, audit and
compliance matters, human resources matters, tax, finance and accounting matters, and business plans.

On July 23, 2025, members of
management of STAAR and Alcon participated in in-person diligence sessions. Among other things, STAAR management presented the July Diligence Projections (as defined in “The Merger—Certain Unaudited Prospective Financial Information”), which were subsequently posted to the diligence dataroom. For more information, see “The Merger—Certain Unaudited Prospective Financial Information.”

From July 15 through August 3, 2025, Mr. Farrell participated in calls and meetings with representatives of Stockholder A,
subject to the previously executed confidentiality agreement, to discuss STAAR’s financial performance and to better understand Stockholder A’s perspective on valuation to assist the Board in making an informed decision as whether to
proceed with a potential transaction with Alcon. Representatives of Stockholder A and Mr. Farrell exchanged perspectives on STAAR’s potential future performance, and the risks and opportunities related thereto.

On July 25, 2025, the Board held a meeting to discuss the status of due diligence and negotiations with Alcon as well as
Mr. Farrell’s interactions with Stockholder A, with members of STAAR’s management and representatives of Wachtell Lipton participating. Representatives of Wachtell Lipton provided an overview of the directors’ fiduci